Senores Pharmaceuticals Q3 Results
- BSE: 544319
- NSE: SENORES
- ISIN: INE0RB801010
- Sector: Biotechnology & Drugs
BSE
820.20
16.05 (2.00%)
16.05 (2.00%)Volume14.58 K
Updated: Fri 10 Apr, 2026 | 15:29:49
NSE
820.1014.75 (1.83%)
14.75 (1.83%)Volume2.22 L
Updated: Fri 10 Apr, 2026 | 15:30:03
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q3 Results Highlights
- Total Income₹174.56 Cr.(69.44%)
- Operating Profit₹46.14 Cr.(114.80%)
- Profit After Tax₹31.66 Cr.(84.39%)
- Operating Margin26.43%(26.77%)
Note: Comparison is on YoY basis
Quarterly - Senores Pharmaceuticals Q3 Results
*All figures in crores except per share values
| Fiscal Period | Dec 25 | Sep 24 | QoQ Comp | Dec 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 128.42 | 81.27 | 6.71% | 81.54 | 57.49% |
| Depreciation/ Amortization | 7.86 | 3.89 | -2.84% | 4.20 | 87.14% |
| Operating Income | 46.14 | 19.36 | 11.40% | 21.48 | 114.80% |
| Net Income | 31.66 | 12.84 | -2.25% | 17.17 | 84.39% |
| Other Operating Expenses Total | 22.88 | 14.76 | -10.42% | 17.63 | 29.78% |
| Net Income Before Taxes | 44.60 | 15.95 | 9.74% | 20.48 | 117.77% |
| Total Revenue | 174.56 | 100.63 | 7.91% | 103.02 | 69.44% |
| Selling/ General/ Admin Expenses Total | 30.66 | 14.70 | 3.48% | 19.01 | 61.28% |
| Diluted Normalized EPS | 7.29 | 3.92 | 11.47% | 5.04 | 44.64% |